Promis Neurosciences (NASDAQ: PMN) is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases. The company is currently under the spotlight due to a recent price target set by H.C. Wainwright. On December 1, 2025, H.C. Wainwright set a price target of $18 for PMN, while the stock was trading at $7.21. This suggests a potential price increase of approximately 50.5%.
Despite the optimistic target from H.C. Wainwright, Promis Neurosciences has received mixed ratings from analysts. The stock has an average rating of "Moderate Buy" from four brokerages. Among these, one analyst has issued a sell rating, while three have given a buy rating. The average 12-month target price from brokers who updated their coverage in the past year is $11, indicating varied expectations.
Recent analyst reports show differing opinions on PMN. Wall Street Zen downgraded the stock to a "strong sell," and Weiss Ratings reaffirmed a "sell (e+)" rating. Conversely, H.C. Wainwright maintained a "buy" rating. Guggenheim also maintained a "buy" rating.
Currently, PMN is priced at $7.08, showing an increase of approximately 4.86% or $0.33. The stock has fluctuated between a low of $6.51 and a high of $7.40 today. Over the past year, PMN has seen a high of $39.75 and a low of $6.27. The company's market capitalization is around $9.25 million, with a trading volume of 45,812 shares on the NASDAQ exchange.
